NF1 mutation

News alerts, weekly reports and conference planners

Entrez ID:

4763

Related biomarkers:

‹

›

NF1 mutation	Glioblastoma	NF1 mutation	Glioblastoma	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
NF1 mutation	CNS Tumor	NF1 mutation	CNS Tumor	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
NF1 mutation	Lung Cancer	NF1 mutation	Lung Cancer	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
NF1 mutation	Glioma	NF1 mutation	Glioma	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3
NF1 mutation	Melanoma	NF1 mutation	Melanoma	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3
NF1 mutation	Thyroid Gland Anaplastic Carcinoma	NF1 mutation	Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3
NF1 mutation	Colorectal Cancer	NF1 mutation	Colorectal Cancer	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3
NF1 mutation	Multiple Myeloma	NF1 mutation	Multiple Myeloma	MEK inhibitor Sensitive: C3 – Early Trials MEK inhibitor Sensitive : C3	MEK inhibitor Sensitive: C3 – Early Trials MEK inhibitor Sensitive : C3
NF1 mutation	Solid Tumor	NF1 mutation	Solid Tumor	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3
NF1 mutation	Melanoma	NF1 mutation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
NF1 mutation	Melanoma	NF1 mutation	Melanoma	PD1 inhibitor + MEK inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + MEK inhibitor Sensitive : C3	PD1 inhibitor + MEK inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + MEK inhibitor Sensitive : C3
NF1 mutation	Soft Tissue Sarcoma	NF1 mutation	Soft Tissue Sarcoma	ifosfamide + pegylated liposomal doxorubicin Resistant: C3 – Early Trials ifosfamide + pegylated liposomal doxorubicin Resistant : C3	ifosfamide + pegylated liposomal doxorubicin Resistant: C3 – Early Trials ifosfamide + pegylated liposomal doxorubicin Resistant : C3
NF1 mutation	Glioblastoma	NF1 mutation	Glioblastoma	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3
NF1 mutation	Glioma	NF1 mutation	Glioma	FCN-159 Sensitive: C3 – Early Trials FCN-159 Sensitive : C3	FCN-159 Sensitive: C3 – Early Trials FCN-159 Sensitive : C3
NF1 mutation	Breast Cancer	NF1 mutation	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
NF1 mutation	Thyroid Gland Medullary Carcinoma	NF1 mutation	Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4
NF1 mutation	Sarcoma	NF1 mutation	Sarcoma	RMC-4630 Sensitive: C4 – Case Studies RMC-4630 Sensitive : C4	RMC-4630 Sensitive: C4 – Case Studies RMC-4630 Sensitive : C4
NF1 mutation	Melanoma	NF1 mutation	Melanoma	VTX-11e Resistant: D – Preclinical VTX-11e Resistant : D	VTX-11e Resistant: D – Preclinical VTX-11e Resistant : D
NF1 mutation	Melanoma	NF1 mutation	Melanoma	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D	PD-0325901 Sensitive: D – Preclinical PD-0325901 Sensitive : D
NF1 mutation	Neurofibrosarcoma	NF1 mutation	Neurofibrosarcoma	DR6MP + JHU395 Sensitive: D – Preclinical DR6MP + JHU395 Sensitive : D	DR6MP + JHU395 Sensitive: D – Preclinical DR6MP + JHU395 Sensitive : D
NF1 mutation	Neurofibrosarcoma	NF1 mutation	Neurofibrosarcoma	DR6MP Sensitive: D – Preclinical DR6MP Sensitive : D	DR6MP Sensitive: D – Preclinical DR6MP Sensitive : D
NF1 mutation	Neurofibrosarcoma	NF1 mutation	Neurofibrosarcoma	MEK inhibitor + c-MET inhibitor Sensitive: D – Preclinical MEK inhibitor + c-MET inhibitor Sensitive : D	MEK inhibitor + c-MET inhibitor Sensitive: D – Preclinical MEK inhibitor + c-MET inhibitor Sensitive : D
NF1 mutation	Non Small Cell Lung Cancer	NF1 mutation	Non Small Cell Lung Cancer	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D
NF1 mutation	Melanoma	NF1 mutation	Melanoma	cobimetinib Sensitive: D – Preclinical cobimetinib Sensitive : D	cobimetinib Sensitive: D – Preclinical cobimetinib Sensitive : D

NF1 mutation

Associations